201 related articles for article (PubMed ID: 34458816)
1. Mechanisms of allosteric and mixed mode aromatase inhibitors.
Souza SA; Held A; Lu WJ; Drouhard B; Avila B; Leyva-Montes R; Hu M; Miller BR; Ng HL
RSC Chem Biol; 2021 Jun; 2(3):892-905. PubMed ID: 34458816
[TBL] [Abstract][Full Text] [Related]
2. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
Murphy MJ
Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
[TBL] [Abstract][Full Text] [Related]
3. The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents.
Lu WJ; Xu C; Pei Z; Mayhoub AS; Cushman M; Flockhart DA
Breast Cancer Res Treat; 2012 May; 133(1):99-109. PubMed ID: 21814747
[TBL] [Abstract][Full Text] [Related]
4. Aromatase inhibitors--mechanisms for non-steroidal inhibitors.
Vanden Bossche HV; Moereels H; Koymans LM
Breast Cancer Res Treat; 1994; 30(1):43-55. PubMed ID: 7949204
[TBL] [Abstract][Full Text] [Related]
5. Computational approaches elucidate the allosteric mechanism of human aromatase inhibition: a novel possible route to Small-molecule regulation of CYP450s activities?
Sgrignani J; Bon M; Colombo G; Magistrato A
J Chem Inf Model; 2014 Oct; 54(10):2856-68. PubMed ID: 25178092
[TBL] [Abstract][Full Text] [Related]
6. Aromatase inhibitors: past, present and future.
Séralini G; Moslemi S
Mol Cell Endocrinol; 2001 Jun; 178(1-2):117-31. PubMed ID: 11403901
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer.
Lu WJ; Desta Z; Flockhart DA
Breast Cancer Res Treat; 2012 Jan; 131(2):473-81. PubMed ID: 21390495
[TBL] [Abstract][Full Text] [Related]
8. Steroidal metabolites transformed by Marchantia polymorpha cultures block breast cancer estrogen biosynthesis.
Hegazy ME; Gamal-Eldeen AM; El-Halawany AM; Mohamed Ael-H; Paré PW
Cell Biochem Biophys; 2012 May; 63(1):85-96. PubMed ID: 22350385
[TBL] [Abstract][Full Text] [Related]
9. Binding characteristics of aromatase inhibitors and phytoestrogens to human aromatase.
Chen S; Kao YC; Laughton CA
J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):107-15. PubMed ID: 9365179
[TBL] [Abstract][Full Text] [Related]
10. Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of estrogen-dependent breast cancer.
Ahmad I; Shagufta
Eur J Med Chem; 2015 Sep; 102():375-86. PubMed ID: 26301554
[TBL] [Abstract][Full Text] [Related]
11. Aromatase inhibitors: new endocrine treatment of breast cancer.
Brueggemeier RW
Semin Reprod Med; 2004 Feb; 22(1):31-43. PubMed ID: 15083379
[TBL] [Abstract][Full Text] [Related]
12. Aromatase inhibitors: a new paradigm in breast cancer treatment.
Narashimamurthy J; Rao AR; Sastry GN
Curr Med Chem Anticancer Agents; 2004 Nov; 4(6):523-34. PubMed ID: 15579017
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the mechanism of aromatase cytochrome P450. A site-directed mutagenesis study.
Kao YC; Korzekwa KR; Laughton CA; Chen S
Eur J Biochem; 2001 Jan; 268(2):243-51. PubMed ID: 11168357
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of transcriptional regulatory elements of the human aromatase cytochrome P450 gene (CYP19).
Toda K; Nomoto S; Shizuta Y
J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):151-9. PubMed ID: 8603036
[TBL] [Abstract][Full Text] [Related]
15. Mutagenesis study at a postulated hydrophobic region near the active site of aromatase cytochrome P450.
Zhou D; Cam LL; Laughton CA; Korzekwa KR; Chen S
J Biol Chem; 1994 Jul; 269(30):19501-8. PubMed ID: 8034720
[TBL] [Abstract][Full Text] [Related]
16. Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients.
Agarwal VR; Bulun SE; Leitch M; Rohrich R; Simpson ER
J Clin Endocrinol Metab; 1996 Nov; 81(11):3843-9. PubMed ID: 8923826
[TBL] [Abstract][Full Text] [Related]
17. Use of aromatase (CYP19) metabolite ratios to characterize electron transfer from NADPH-cytochrome P450 reductase.
Grogan J; Shou M; Zhou D; Chen S; Korzekwa KR
Biochemistry; 1993 Nov; 32(45):12007-12. PubMed ID: 8218277
[TBL] [Abstract][Full Text] [Related]
18. Relationship between aromatase and cyclooxygenases in breast cancer: potential for new therapeutic approaches.
Brueggemeier RW; Díaz-Cruz ES
Minerva Endocrinol; 2006 Mar; 31(1):13-26. PubMed ID: 16498361
[TBL] [Abstract][Full Text] [Related]
19. Human placental estrogen synthetase (aromatase). Effect of environment on the kinetics of protein-protein and substrate-protein interactions and the production of 19-oxygenated androgen intermediates in the purified reconstituted cytochrome P450 enzyme system.
Sethumadhavan K; Bellino FL
J Steroid Biochem Mol Biol; 1991 Sep; 39(3):381-94. PubMed ID: 1911429
[TBL] [Abstract][Full Text] [Related]
20. Integrated in silico-in vitro strategy for screening of some traditional Egyptian plants for human aromatase inhibitors.
Dawood HM; Ibrahim RS; Shawky E; Hammoda HM; Metwally AM
J Ethnopharmacol; 2018 Oct; 224():359-372. PubMed ID: 29909120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
